KOL Views: How impactful are SGLT-2 inhibitors likely to be in heart failure?

Rivals got the jump on Farxiga (dapagliflozin) in demonstrating an ability to reduce cardiovascular risk in type II diabetics. However, this week AstraZeneca reported top-line results from the DAPA-HF study suggesting its SGLT-2 inhibitor achieved similar results in heart failure patients with reduced ejection fraction (HFrEF) – making it the first of the class to reduce risk in a trial involving non-diabetics.

To provide FirstWord readers with rapid feedback on how SGLT-2 inhibitors like Farxiga might change prescribing patterns outside of diabetes, we are hosting an expert call with a key opinion leader (KOL) later this week.

Key topics that will be discussed during the call include, among other things… is Farxiga’s top-line success in DAPA-HF a big deal; what will you be most interested to see when the detailed data are revealed; how much of a reduction in cardiovascular outcomes, particularly in non-diabetics, would Farxiga need to achieve to change prescribing patterns; where in the treatment algorithm might SGLT-2 inhibitors fit in; how familiar with SGLT-2 inhibitors are physicians who treat HFrEF and will this be a significant barrier to use; do you expect that other SGLT-2 inhibitors like Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) will prove similarly effective in heart failure; will Jardiance head start in receiving a cardiovascular risk reduction claim give it a leg up in HFrEF or, on the contrary, might Farxiga being the first to show a benefit in this setting give it an first-mover advantage?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to potential use of SGLT-2 inhibitors for treating heart failure.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.